Diabetes Health Type 1 & 2: Beyond A1C: Metrics That Matter for Diabetes Management
Sponsored by Lilly Diabetes
A1C is the most accepted measurement among healthcare providers to evaluate long-term glycemic control1, but it isn’t the only measurement that matters. For people living with diabetes, managing glucose levels – especially after meals – can be difficult, which is why taking a deeper look into metrics that contribute to A1C is so important.
People with diabetes often experience short-term fluctuations in glucose that cannot be measured by A1C levels.1Additionally, blood glucose after eating, also known as postprandial glucose (PPG), can contribute to a lack of glycemic control and high A1C.2 Monitoring PPG can help people with diabetes better understand the bigger picture of managing their condition, in addition to how PPG levels may impact their time in range (TIR). TIR can show the variability in glucose levels3 and can be different from person to person depending on administration of insulin. Ultimately, it can either positively or negatively affect A1C.
The impact of metrics like PPG and TIR, among others, on condition management shows just how important it is that people have options for therapies that work to improve their day-to-day and longer-term goals. Research on patient perspectives show that when it comes to treatments that work directly to increase TIR and other positive diabetes outcomes, current diabetes treatments often fall short.3 Lilly Diabetes aims to look at the bigger picture, which is why we are measuring TIR and PPG in our research to support the development of new medicines and solutions that better meet the ever-changing needs of people living with diabetes.
New developments in diabetes treatment and technologies have made it easier for people with diabetes to see and evaluate their glucose levels throughout the day, but it is a continuous effort to meet their goals on a daily basis.4 Understanding PPG and its relationship to A1C is an important part of managing diabetes.1,2 With the help of continued research and innovative treatments, people living with diabetes may be able to achieve more control over blood glucose levels.
Click here to learn more about a mealtime insulin option: https://e.lilly/2RA3yKq
PP-UR-US-0279 01/2021 ©Lilly USA, LLC 2021. All rights reserved.
- American Diabetes Association. Postprandial Blood Glucose. Diabetes Care. 2001; 24(4):775-778. https://doi.org/10.2337/diacare.24.4.775
- American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes – 2020. Diabetes Care. 2020; 43(Suppl. 1): S66-S76. https://doi.org/10.2337/dc20-S006
- Runge, Ava S, et al. Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes. Clin Diabetes, American. Diabetes Association, Apr. 2018. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC5898169/.
- Beck RW, et al. Advances in technology for management of type 1 diabetes. Lancet. 2019 Sept 15; 394(10205):1265-1273. https://doi.org/10.1016/S0140-6736(19)31142-0